tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

KYMR Stock Latest News

Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls
The FlyReddit initiated, Pinterest upgraded: Wall Street’s top analyst calls
10d ago
AAP
CAH
Kymera Therapeutics price target raised to $60 from $52 at Guggenheim
PremiumThe Fly
Kymera Therapeutics price target raised to $60 from $52 at Guggenheim
10d ago
KYMR
Kymera Therapeutics’ KT-621 Shows Promising Trial Results, Supporting Buy Rating
PremiumRatings
Kymera Therapeutics’ KT-621 Shows Promising Trial Results, Supporting Buy Rating
10d ago
KYMR
Promising Potential of Kymera Therapeutics’ KT-621: Strong Therapeutic Effect and Buy Rating Affirmed
PremiumRatings
Promising Potential of Kymera Therapeutics’ KT-621: Strong Therapeutic Effect and Buy Rating Affirmed
10d ago
KYMR
Kymera Therapeutics price target raised to $64 from $57 at JPMorgan
PremiumThe Fly
Kymera Therapeutics price target raised to $64 from $57 at JPMorgan
10d ago
KYMR
Kymera Therapeutics upgraded to Buy from Neutral at B. Riley
PremiumThe FlyKymera Therapeutics upgraded to Buy from Neutral at B. Riley
10d ago
KYMR
Kymera Therapeutics’ KT-621 Shows Promising Potential, Upgraded to Overweight with $79 Target
Premium
Ratings
Kymera Therapeutics’ KT-621 Shows Promising Potential, Upgraded to Overweight with $79 Target
11d ago
KYMR
Kymera Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
Premium
The Fly
Kymera Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
11d ago
KYMR
Kymera Therapeutics price target raised to $60 from $52 at Citi
PremiumThe Fly
Kymera Therapeutics price target raised to $60 from $52 at Citi
11d ago
KYMR
Kymera Therapeutics upgraded to Buy at BofA after KT-621 data
PremiumThe Fly
Kymera Therapeutics upgraded to Buy at BofA after KT-621 data
11d ago
KYMR
Kymera Therapeutics upgraded to Buy from Neutral at BofA
PremiumThe Fly
Kymera Therapeutics upgraded to Buy from Neutral at BofA
11d ago
KYMR
Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6
PremiumThe Fly
Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6
11d ago
SNY
KYMR
Kymera Therapeutics Discusses Phase 1 Study Results
PremiumCompany AnnouncementsKymera Therapeutics Discusses Phase 1 Study Results
11d ago
8K
KYMR
Kymera Therapeutics Announces Positive Phase 1 Study Results
Premium
Company Announcements
Kymera Therapeutics Announces Positive Phase 1 Study Results
11d ago
8K
KYMR
Kymera Therapeutics announces first-in-human results for Phase 1 trial of KT-621
Premium
The Fly
Kymera Therapeutics announces first-in-human results for Phase 1 trial of KT-621
11d ago
KYMR
Cautious Hold Rating for Kymera Therapeutics Amid Anticipation of STAT6 Degrader Data
PremiumRatings
Cautious Hold Rating for Kymera Therapeutics Amid Anticipation of STAT6 Degrader Data
11d ago
KYMR
Hold Rating for Kymera Therapeutics Due to Uncertainties in KT-621 Development and Need for Clinical De-risking
PremiumRatings
Hold Rating for Kymera Therapeutics Due to Uncertainties in KT-621 Development and Need for Clinical De-risking
14d ago
KYMR
Kymera Therapeutics: Promising Growth in Biotechnology with Innovative Degrader Platform and Strategic Partnerships
PremiumRatings
Kymera Therapeutics: Promising Growth in Biotechnology with Innovative Degrader Platform and Strategic Partnerships
24d ago
KYMR
Kymera Therapeutics resumed with a Buy at Stifel
PremiumThe Fly
Kymera Therapeutics resumed with a Buy at Stifel
24d ago
KYMR
Kymera Therapeutics presents preclinical data for KT-621
PremiumThe FlyKymera Therapeutics presents preclinical data for KT-621
25d ago
KYMR
Kymera Therapeutics price target lowered to $70 from $72 at UBS
Premium
The Fly
Kymera Therapeutics price target lowered to $70 from $72 at UBS
1M ago
KYMR
Kymera Therapeutics’ Innovative IRF5 Degrader KT-579 Fuels Buy Rating with Promising Growth in Immunology
Premium
Ratings
Kymera Therapeutics’ Innovative IRF5 Degrader KT-579 Fuels Buy Rating with Promising Growth in Immunology
1M ago
KYMR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >